Drugs / AZD6482
AZD6482
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00853450 | Feb → Jul 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00688714 | Jan → May 2008 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6482 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00688714 ↗ |
| Known as | 4URK | ChEMBL registry synonym — accepted as the source's own label CHEMBL2165191 ↗ |
| Known as | KIN 193 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2165191 ↗ |
| Known as | KIN001-193 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2165191 ↗ |
| Known as | WO2009093972 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2165191 ↗ |
| Modality | Small molecule | — CHEMBL2165191 ↗ |
| Route | Intravenous | “0,9-364,5 mg administrated through intravenous infusion over 3 hours” NCT00688714 ↗ |